| May 28, 2015 | ISSUE NUMBER 402 VOL 4 |
Top Story
Hot and Cold: The Latest Biotech M&A and Financial Trends
The overall impression from the news media that the biotech industry is doing a great job inventing new drugs and treatments and that, for the moment, strong companies are getting the funding they need, is not quite the full picture, as Peter Young explains
...Read more
Regulatory
“Cures” Debate Far From Over
The House Energy & Commerce (E&C) Committee unanimously approved the 21st Century Cures legislation last week, but the debate is slated to continue for several months, if not longer. Jill Wechsler reports
...Read more
Generic Opioids Raise Tricky Policy Issues
Widespread use and abuse of opioid painkillers is prompting efforts to develop new drugs and formulations that resist abuse while providing relief to legitimate patients, writes Jill Wechsler
...Read more
Priority Review Voucher Priced at $245m
A hot commodity, the FDA's Rare Pediatric Disease Priority Review Voucher program once again proved its worth, with yesterday's $245m transaction
...Read more
Sales
Do Sales Reps Hold the Key to Better Insights
Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed, writes Dr Pamela Walker
...Read more
Education
Health Innovation 101: Institutionalizing the Teachable Moment with GENiE
William Looney reports on a meeting of a unique network of 19 US and European academic programs focused on building an inventory of shared learning and best practices in health innovation to drive reforms in both the public and private sectors
...Read more
How Changes in the Healthcare Environment Mean New Marketing Opportunities for Pharmaceutical Providers
As the healthcare industry undergoes significant change, physicians and other healthcare providers are forced to find new ways to stay informed and meet increased demands. To help them, their circle of influence has widened, including digital sources, social media, online forums, traditional journal articles by key opinion leaders, and even the patients themselves. Meanwhile, pharmaceutical companies are looking for new opportunities of their own to help get their products in front of a new generation of healthcare providers. Discover the right tools to help do it.
 Learn more
|
|
|
 //REGENXBIO (Rockville, MD) announced the appointment of Jerry Karabelas, Ph.D., to its Board of Directors. //BioSig Technologies (Minneapolis, MN) appointed David Weild to the Board of Directors, effective immediately. Mr. Weild has been elected to Chair the Audit Committee of the Board as the company prepares to uplist to a National Stock Exchange.//NeoStem (New York, NY) appointed Dr. Merrick Ross, Professor of Surgery and Chief of the Melanoma Section, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, as the lead principal investigator for its Intus study. //Cancer Genetics (Rutherford, NJ, and Hyderabad, India) appointed Mandar Kulkarni, PhD., as Chief Technology Officer (CTO) of Cancer Genetics, India, based in Hyderabad. //Advaxis (Princeton, NJ) named Fred J. Frullo as Vice President, Regulatory Affairs. // |
|
|
|
|
|
